All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Multiple Myeloma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2021-06-24T08:24:59.000Z

The EC has extended marketing authorization for SC daratumumab + Pd for the treatment of R/R MM

Jun 24, 2021
Share:

Bookmark this article

On June 22, 2021, it was announced that the European Commission (EC) granted an extended marketing authorization for the use of subcutaneous (SC) daratumumab in combination with pomalidomide and dexamethasone (Pd) for the treatment of adults with relapsed/refractory (R/R) multiple myeloma (MM). The new indication is for patients who have received one prior therapy containing a proteasome inhibitor and lenalidomide and who are lenalidomide refractory, or for patients who have received ≥2 prior therapies that included lenalidomide and a proteasome inhibitor and who have demonstrated disease progression on or after the last therapy.1

The approval was based on results from the phase III APOLLO trial (NCT03180736), previously published on the Multiple Myeloma Hub, which showed that the addition of daratumumab to Pd reduced the risk of progression or death by 37% compared with Pd alone (hazard ratio, 0.63; 95% confidence interval, 0.47–0.85; p = 0.0018).1,2

  1. Janssen. DARZALEX®▼ (daratumumab) subcutaneous (sc) formulation becomes the first approved treatment for newly diagnosed systemic light chain amyloidosis in Europe and gains an additional approval in pre-treated multiple myeloma. http://johnsonandjohnson.gcs-web.com/static-files/59e7757b-4327-40ce-89a5-5b81ae2b4152. Published Jun 22, 2021. Accessed Jun 23, 2021.
  2. Dimopoulos MA, Terpos E, Boccadoro M, et al. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22(6):801-812. DOI: 1016/S1470-2045(21)00128-5

Newsletter

Subscribe to get the best content related to multiple myeloma delivered to your inbox